털곰팡이증 Amphotericin B 치료 실패 후 Posaconazole로 호전된 = intectious disease A case of successful posaconazole salvage therapy for rhinocerebral mucormycosis after failure of amphotericin B

다국어 초록 (Multilingual Abstract)

A 58-year-old man with uncontrolled type 2 diabetes mellitus developed rhinocerebral mucormycosis. The infection progressed to intracranial extension despite more than 5 weeks of treatment with amphotericin B. The patient then received oral posaconazole, 800 mg/d, in divided doses for 6 months. Salvage treatment with the new azole antifungal posaconazole resulted in dramatic clinical improvement as early as 1 week after the initiation of therapy. Oral posaconazole continued through 24 weeks of treatment, with marked clinical, mycological, and radiological improvements and no adverse events. Here we review the medical literature on rhinocerebral mucormycosis, which is a rapidly progressive and often fatal infection. The treatment of choice is amphotericin B, which failed in our patient. Our case report suggests that posaconazole appears to be a well tolerated and effective salvage treatment option for rhinocerebral mucormycosis, including disseminated disease. (Korean J Med 79:587-591, 2010)

참고문헌 (Reference)

1 이광우, "당뇨성 케톤증에 합병된 비뇌 Mucor 진균증 1예" 25 : 91-95, 1982

2 전영주, "당뇨성 케톤산증에서 폐농양이 합병된 기관지모균증 1예" 38 : 317-323, 1991

3 박명규, "당뇨병에 합병된 비안와형 모균증 1예" 47 : 569-574, 1994

4 정희, "당뇨병에 합병된 비대뇌 모균증 1예" 39 : 715-721, 1990

5 Perfect JR, "Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex" 40 (40): S401-S408, 2005

6 Gale GR, "Studies of opportunistic fungi" 241 : 604-612, 1961

7 Schwartz JC, "Rhinocerebral mucormycosis. Three case reports and subject review" 3 : 9-11, 1985

8 Simmons JH, "Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature" 6 : 234-238, 2005

9 Medoff G, "Pulmonary mucormycosis" 286 : 86-87, 1972

10 Torres HA, "Posaconazole: a broad-spectrum triazole antifungal" 5 : 775-785, 2005

11 Concoran G, "Posaconazole therapy for refractory invasive zycomycosis( poster)" 17-20, 2004

12 Langner S, "Posaconazole in the management of refractory invasive fungal infections" 4 : 747-758, 2008

13 Perkhofer S, "Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro" 52 : 2636-2638, 2008

14 Segal BH, "Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection" 40 : 1684-1688, 2005

15 Greenberg RN, "Posaconazole as salvage therapy for zygomycosis" 50 : 126-133, 2006

16 Green WH, "Mucormycosis infection of the craniofacial structure" 101 : 802-806, 1967

17 Tarani L, "Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl" 10 : 289-293, 2009

18 Roden MM, "Epidemiology and outcome of zygomycosis: a review of 929 reported cases" 41 : 634-653, 2005

19 Radner AB, "Acute invasive, rhinocerebral zygomycosis in an otherwise healthy patient: case report and review" 20 : 163-166, 1995

20 Alastruey-Izquierdo A, "Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers" 53 : 1686-1689, 2009